Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease

Peter J. Kudenchuk, Jack Kron, Charles G. Walance, Joel E. Cutler, Karen K. Griffith, John H. McAnulty

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Forty-nine patients with coronary artery disease and documented clinical sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) were studied twice in the drug-free state and twice during treatment with an identical antiarrhythmic medication at therapeutic plasma concentrations using an identical programmed electrical stimulation protocol. Tested drugs included procainamide, quinidine, disopyramide and phenytoin. During their 2 paired tests, 11 patients had nearly identical therapeutic plasma concentrations of antiarrhythmic agents (group I) and 38 patients had therapeutic plasma concentrations, but with more variation in drug levels between otherwise identical paired drug tests (group II). Overall, 71% of patients had inducible sustained VT or VF during drug testing. Induced ventricular arrhythmias were not reproducible in 45% of group I patients, despite restudy at nearly identical therapeutic plasma concentrations of an identical antiarrhythmic agent. Induced arrhythmias were also not reproducible in 16% of group II patients. This variability could not be attributed to the electrophysiologic characteristics of the patients studied. Drug trials directed by programmed stimulation should be cautiously interpreted because time-associated changes can mimic a change attributed to a beneficial or deleterious drug effect.

Original languageEnglish (US)
Pages (from-to)725-730
Number of pages6
JournalThe American Journal of Cardiology
Volume66
Issue number7
DOIs
StatePublished - Sep 15 1990

Fingerprint

Anti-Arrhythmia Agents
Tachycardia
Coronary Artery Disease
Pharmaceutical Preparations
Ventricular Fibrillation
Ventricular Tachycardia
Cardiac Arrhythmias
Disopyramide
Therapeutics
Procainamide
Quinidine
Phenytoin
Electric Stimulation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease. / Kudenchuk, Peter J.; Kron, Jack; Walance, Charles G.; Cutler, Joel E.; Griffith, Karen K.; McAnulty, John H.

In: The American Journal of Cardiology, Vol. 66, No. 7, 15.09.1990, p. 725-730.

Research output: Contribution to journalArticle

Kudenchuk, Peter J. ; Kron, Jack ; Walance, Charles G. ; Cutler, Joel E. ; Griffith, Karen K. ; McAnulty, John H. / Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease. In: The American Journal of Cardiology. 1990 ; Vol. 66, No. 7. pp. 725-730.
@article{7814281cec5246f0b4d48c8e865a2ec3,
title = "Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease",
abstract = "Forty-nine patients with coronary artery disease and documented clinical sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) were studied twice in the drug-free state and twice during treatment with an identical antiarrhythmic medication at therapeutic plasma concentrations using an identical programmed electrical stimulation protocol. Tested drugs included procainamide, quinidine, disopyramide and phenytoin. During their 2 paired tests, 11 patients had nearly identical therapeutic plasma concentrations of antiarrhythmic agents (group I) and 38 patients had therapeutic plasma concentrations, but with more variation in drug levels between otherwise identical paired drug tests (group II). Overall, 71{\%} of patients had inducible sustained VT or VF during drug testing. Induced ventricular arrhythmias were not reproducible in 45{\%} of group I patients, despite restudy at nearly identical therapeutic plasma concentrations of an identical antiarrhythmic agent. Induced arrhythmias were also not reproducible in 16{\%} of group II patients. This variability could not be attributed to the electrophysiologic characteristics of the patients studied. Drug trials directed by programmed stimulation should be cautiously interpreted because time-associated changes can mimic a change attributed to a beneficial or deleterious drug effect.",
author = "Kudenchuk, {Peter J.} and Jack Kron and Walance, {Charles G.} and Cutler, {Joel E.} and Griffith, {Karen K.} and McAnulty, {John H.}",
year = "1990",
month = "9",
day = "15",
doi = "10.1016/0002-9149(90)91138-V",
language = "English (US)",
volume = "66",
pages = "725--730",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease

AU - Kudenchuk, Peter J.

AU - Kron, Jack

AU - Walance, Charles G.

AU - Cutler, Joel E.

AU - Griffith, Karen K.

AU - McAnulty, John H.

PY - 1990/9/15

Y1 - 1990/9/15

N2 - Forty-nine patients with coronary artery disease and documented clinical sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) were studied twice in the drug-free state and twice during treatment with an identical antiarrhythmic medication at therapeutic plasma concentrations using an identical programmed electrical stimulation protocol. Tested drugs included procainamide, quinidine, disopyramide and phenytoin. During their 2 paired tests, 11 patients had nearly identical therapeutic plasma concentrations of antiarrhythmic agents (group I) and 38 patients had therapeutic plasma concentrations, but with more variation in drug levels between otherwise identical paired drug tests (group II). Overall, 71% of patients had inducible sustained VT or VF during drug testing. Induced ventricular arrhythmias were not reproducible in 45% of group I patients, despite restudy at nearly identical therapeutic plasma concentrations of an identical antiarrhythmic agent. Induced arrhythmias were also not reproducible in 16% of group II patients. This variability could not be attributed to the electrophysiologic characteristics of the patients studied. Drug trials directed by programmed stimulation should be cautiously interpreted because time-associated changes can mimic a change attributed to a beneficial or deleterious drug effect.

AB - Forty-nine patients with coronary artery disease and documented clinical sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) were studied twice in the drug-free state and twice during treatment with an identical antiarrhythmic medication at therapeutic plasma concentrations using an identical programmed electrical stimulation protocol. Tested drugs included procainamide, quinidine, disopyramide and phenytoin. During their 2 paired tests, 11 patients had nearly identical therapeutic plasma concentrations of antiarrhythmic agents (group I) and 38 patients had therapeutic plasma concentrations, but with more variation in drug levels between otherwise identical paired drug tests (group II). Overall, 71% of patients had inducible sustained VT or VF during drug testing. Induced ventricular arrhythmias were not reproducible in 45% of group I patients, despite restudy at nearly identical therapeutic plasma concentrations of an identical antiarrhythmic agent. Induced arrhythmias were also not reproducible in 16% of group II patients. This variability could not be attributed to the electrophysiologic characteristics of the patients studied. Drug trials directed by programmed stimulation should be cautiously interpreted because time-associated changes can mimic a change attributed to a beneficial or deleterious drug effect.

UR - http://www.scopus.com/inward/record.url?scp=0025072175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025072175&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(90)91138-V

DO - 10.1016/0002-9149(90)91138-V

M3 - Article

C2 - 2399890

AN - SCOPUS:0025072175

VL - 66

SP - 725

EP - 730

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 7

ER -